AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27502121 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable heart failure with reduced ejection fraction (≤40%)
Number of subjects: 5276
Study 27502603 — intervention group
Group type: EXPERIMENTAL
Intervention: T2* dynamic-susceptibility contrast MRI (DSC-MRI) and diffusion-weighted imaging (DWI) before radiotherapy and every 2 months thereafter until relapse.
Number of subjects: 44
Study 27502603 — intervention group
Group type: EXPERIMENTAL
Intervention: Voxels thresholded for hyperperfused areas using a 1.75 fixed rCBV threshold.
Number of subjects: 44
Study 27502708 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisertib 50 mg PO b.i.d. d1-d7 every 21 days
Number of subjects: 72
Study 27502712 — intervention group
Group type: EXPERIMENTAL
Intervention: MAGE-A3 immunotherapeutic
Number of subjects: 123
Study 27502759 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet Mindfulness Meditation Intervention (IMMI)
Number of subjects: 44
Study 27502759 — intervention group
Group type: COMPARATOR
Intervention: Access to Guided Meditation
Number of subjects: 44
Study 27502768 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusively breastfed
Number of subjects: 427
Study 27502768 — intervention group
Group type: COMPARATOR
Intervention: Exclusively formula-fed
Number of subjects: 427
Study 27502768 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-fed
Number of subjects: 427
Study 27502804 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based exercise (WBE)
Number of subjects: 25
Study 27502804 — intervention group
Group type: EXPERIMENTAL
Intervention: Land-based exercise (LBE)
Number of subjects: 25
Study 27502866 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 12944
Study 27502866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12944
Study 27502928 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin or Doxycycline (exact dosage and duration not specified)
Number of subjects: 400
Study 27502928 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-collection of anorectal and vaginal swabs before treatment and at weeks 1, 2, 4, 6, 8, 10, and 12
Number of subjects: 400
Study 27502928 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression models assessing impact of sexual exposure and alternate anatomic site of infection
Number of subjects: 400
Study 27503501 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent ibrutinib
Number of subjects: 96
Study 27503642 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam (single 2-h intravenous infusion); cohort 1: 2,000 to 500 mg; cohort 2: 2,000 to 500 mg [≥40 kg] or 50 to 12.5 mg/kg [<40 kg]; cohorts 3 and 4: 50 to 12.5 mg/kg
Number of subjects: 32
Study 27503642 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam
Number of subjects: 32
Study 27504001 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricuspid aortic valve (TAV)
Number of subjects: 200
Study 27504001 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicuspid aortic valve (BAV)
Number of subjects: 200
Study 27504001 — intervention group
Group type: EXPERIMENTAL
Intervention: TAV in younger patients (<72 years old)
Number of subjects: 200
Study 27504001 — intervention group
Group type: EXPERIMENTAL
Intervention: TAV in older patients (≥72 years old)
Number of subjects: 200
Study 27504001 — intervention group
Group type: EXPERIMENTAL
Intervention: BAV in younger patients (<51 years old)
Number of subjects: 200
Study 27504001 — intervention group
Group type: EXPERIMENTAL
Intervention: BAV in older patients (≥51 years old)
Number of subjects: 200
Study 27504001 — intervention group
Group type: EXPERIMENTAL
Intervention: AVCd
Number of subjects: 200
Study 27504001 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 200
Study 27504002 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT)
Number of subjects: 10568
Study 27504002 — intervention group
Group type: COMPARATOR
Intervention: DAPT interruption
Number of subjects: 10568
Study 27504002 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT
Number of subjects: 10568
Study 27504087 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast
Number of subjects: 1
Study 27504630 — intervention group
Group type: EXPERIMENTAL
Intervention: IgM-enriched immunoglobulin (IgM-IVIg) (5 mg/kg/d over three days)
Number of subjects: 26
Study 27504630 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study 27504830 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of stroke (FH+)
Number of subjects: 382
Study 27504830 — intervention group
Group type: COMPARATOR
Intervention: Family history of coronary heart disease (FH+ CHD)
Number of subjects: 382
Study 27504830 — intervention group
Group type: COMPARATOR
Intervention: Family history of peripheral artery disease (FH+ PAD)
Number of subjects: 382
Study 27506223 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application for insulin titration
Number of subjects: 0
Study 27506223 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study 27506279 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental or caretaker assistance in stool sampling initiation
Number of subjects: 72
Study 27506279 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental assistance in placement of stool in the container
Number of subjects: 72
Study 27506279 — intervention group
Group type: EXPERIMENTAL
Intervention: Teenagers' feelings about stool sampling
Number of subjects: 72
Study 27506279 — intervention group
Group type: EXPERIMENTAL
Intervention: Role of parents or caretakers in stool sampling
Number of subjects: 72
Study 27506279 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomy in stool sampling
Number of subjects: 72
Study 27506432 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominoperineal excision (APE) for rectal cancer
Number of subjects: 545
Study 27507113 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine chloride supplementation (115 mmol/d for 3 days)
Number of subjects: 172
Study 27507113 — intervention group
Group type: COMPARATOR
Intervention: Hypochloremia (chloride ≤96 mmol/L)
Number of subjects: 172
Study 27507156 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with atypical femur fractures (AFF)
Number of subjects: 23
Study 27507156 — intervention group
Group type: COMPARATOR
Intervention: Control patients taking long term bisphosphonates
Number of subjects: 23
Study 27507156 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical femur fracture patients
Number of subjects: 23
Study 27507156 — intervention group
Group type: COMPARATOR
Intervention: Both cohorts (AFF and control)
Number of subjects: 23
Study 27507228 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 38
Study 27507877 — intervention group
Group type: EXPERIMENTAL
Intervention: Selinexor (30 mg/m²) in combination with fludarabine and cytarabine
Number of subjects: 18
Study 27507877 — intervention group
Group type: COMPARATOR
Intervention: Fludarabine and Cytarabine (without Selinexor)
Number of subjects: 18
Study 27508494 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood pneumonia cases (843)
Number of subjects: 843
Study 27508494 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime pneumonia cases (3,766)
Number of subjects: 843
Study 27508494 — intervention group
Group type: COMPARATOR
Intervention: Control subjects for childhood pneumonia (9,091)
Number of subjects: 843
Study 27508494 — intervention group
Group type: COMPARATOR
Intervention: Control subjects for lifetime pneumonia (5,659)
Number of subjects: 843
Study 27509100 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymectomy plus alternate-day prednisone
Number of subjects: 126
Study 27509100 — intervention group
Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 126
Study 27509385 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted temperature management at 33.0°C (hypothermia)
Number of subjects: 295
Study 27509385 — intervention group
Group type: COMPARATOR
Intervention: Targeted temperature management at 36.8°C (normothermia)
Number of subjects: 295
Study 27509385 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital discharge Pediatric Cerebral Performance Category scores
Number of subjects: 295
Study 27509385 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-month Vineland Adaptive Behavior Scale scores
Number of subjects: 295
Study 27509385 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia treatment
Number of subjects: 295
Study 27510328 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI data quality assessment plot
Number of subjects: 0
Study 27510535 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish-oil therapy
Number of subjects: 182
Study 27512620 — intervention group
Group type: EXPERIMENTAL
Intervention: Ester-C(®) (EC, 1000 mg vitamin C)
Number of subjects: 36
Study 27512620 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL, 0 mg vitamin C)
Number of subjects: 36
Study 27512620 — intervention group
Group type: COMPARATOR
Intervention: Ascorbic acid (AA, 1000 mg vitamin C)
Number of subjects: 36
Study 27512970 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL cholesterol
Number of subjects: 7641
Study 27512970 — intervention group
Group type: EXPERIMENTAL
Intervention: non-HDL cholesterol
Number of subjects: 7641
Study 27512970 — intervention group
Group type: EXPERIMENTAL
Intervention: total cholesterol
Number of subjects: 7641
Study 27512970 — intervention group
Group type: EXPERIMENTAL
Intervention: apolipoprotein B
Number of subjects: 7641
Study 27514314 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-hypofractionated radiation treatment
Number of subjects: 0
Study 27514463 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy guided by pharmacogenetic testing
Number of subjects: 0
Study 27514463 — intervention group
Group type: COMPARATOR
Intervention: Standard statin therapy without pharmacogenetic guidance
Number of subjects: 0
Study 27514750 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsening heart failure (WHF)
Number of subjects: 668
Study 27514750 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsening heart failure (WHF) in ROSE
Number of subjects: 668
Study 27514750 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsening heart failure (WHF) in DOSE
Number of subjects: 668
Study 27514750 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of WHF between baseline to 24 hours
Number of subjects: 668
Study 27514750 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of WHF between 24 to 48 hours
Number of subjects: 668
Study 27515038 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing through a facemask with 7.5 cmH2O inspiratory and/or expiratory resistors
Number of subjects: 13
Study 27515128 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetic acid chromoendoscopy (AAC) with 1.5% acetic acid instillation
Number of subjects: 126
Study 27515128 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetic acid chromoendoscopy (AAC)
Number of subjects: 126
Study 27515162 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 1 phase angle measurement at ICU admission
Number of subjects: 931
Study 27515162 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 1 phase angle
Number of subjects: 931
Study 27515162 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 931
Study 27515162 — intervention group
Group type: EXPERIMENTAL
Intervention: APACHE II score
Number of subjects: 931
Study 27515162 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical patient status
Number of subjects: 931
Study 27515162 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission for other diagnosis
Number of subjects: 931
Study 27515162 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable combined score
Number of subjects: 931
Study 27515173 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) and self-determination theory (SDT) based intervention over 12 weeks
Number of subjects: 0
Study 27515173 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 27515248 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose humanized anti-CD20 antibody, veltuzumab
Number of subjects: 50
Study 27515248 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 50
Study 27515247 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome prevalence
Number of subjects: 650
Study 27515247 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-specific cumulative prevalence
Number of subjects: 650
Study 27515247 — intervention group
Group type: EXPERIMENTAL
Intervention: Components of metabolic syndrome
Number of subjects: 650
Study 27515247 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for metabolic syndrome
Number of subjects: 650
Study 27515247 — intervention group
Group type: EXPERIMENTAL
Intervention: Patterns of metabolic abnormalities
Number of subjects: 650
Study 27515250 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib plus steroids as induction
Number of subjects: 51
Study 27515250 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib plus chemotherapy during consolidation
Number of subjects: 51
Study 27515250 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib induction with a more than 1.3 log-reduction of BCR-ABL1 levels
Number of subjects: 51
Study 27515250 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival and disease-free survival at 60 months
Number of subjects: 51
Study 27515308 — intervention group
Group type: EXPERIMENTAL
Intervention: AMSCs grown in human platelet lysate (hPL)
Number of subjects: 15
Study 27515583 — intervention group
Group type: EXPERIMENTAL
Intervention: ArmeoSenso (IMU-based virtual reality system)
Number of subjects: 11
Study 27516088 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol/Glycopyrronium (IND/GLY)
Number of subjects: 0
Study 27516088 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol/Fluticasone combination (SFC)
Number of subjects: 0
Study 27516462 — intervention group
Group type: COMPARATOR
Intervention: No early recurrences (ER) of atrial tachyarrhythmia
Number of subjects: 401
Study 27516462 — intervention group
Group type: EXPERIMENTAL
Intervention: Early recurrences (ER) during the first month post ablation
Number of subjects: 401
Study 27516462 — intervention group
Group type: EXPERIMENTAL
Intervention: Early recurrences (ER) during the second month post ablation
Number of subjects: 401
Study 27516462 — intervention group
Group type: EXPERIMENTAL
Intervention: Early recurrences (ER) during the third month post ablation
Number of subjects: 401
Study 27516747 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based micro-interventions (techniques: viscerosensory attention, emotional imagery, facial expression, contemplative repetition)
Number of subjects: 27
Study 27516747 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based micro-interventions
Number of subjects: 27
Study 27519353 — intervention group
Group type: EXPERIMENTAL
Intervention: HIPEC
Number of subjects: 22
Study 27519353 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 22
Study 27519448 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal mucosal resurfacing (DMR)
Number of subjects: 39
Study 27519448 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 39
Study 27519585 — intervention group
Group type: EXPERIMENTAL
Intervention: Margin-directed neoadjuvant radiotherapy
Number of subjects: 0
Study 27519585 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigator GTV volumes
Number of subjects: 0
Study 27519585 — intervention group
Group type: EXPERIMENTAL
Intervention: Modelled toxicity risk (NTCP)
Number of subjects: 0
Study 27520560 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular subtypes of PDAC
Number of subjects: 118
Study 27520560 — intervention group
Group type: EXPERIMENTAL
Intervention: HNF1A/B expression levels
Number of subjects: 118
Study 27520560 — intervention group
Group type: EXPERIMENTAL
Intervention: Regulatory network analysis
Number of subjects: 118
Study 27520560 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcription factors (TFs)
Number of subjects: 118
Study 27520860 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 27520989 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine 5 mg twice daily (adjusted to 7.5 mg twice daily if HR >60 bpm)
Number of subjects: 70
Study 27520989 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy (control group)
Number of subjects: 70
Study 27521361 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV-viremic PWID
Number of subjects: 4
Study 27521361 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation of injection drug use
Number of subjects: 4
Study 27521361 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV-viremic individuals who previously were PWID
Number of subjects: 4
Study 27521361 — intervention group
Group type: EXPERIMENTAL
Intervention: Former injection drug users who are HCV aviremic
Number of subjects: 4
Study 27521361 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 4
Study 27521362 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimera 1 (100 PFU)
Number of subjects: 36
Study 27521362 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimera 2 (100 PFU and 1000 PFU)
Number of subjects: 36
Study 27521362 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimera 3
Number of subjects: 36
Study 27521362 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimera 4 (10 PFU, 100 PFU, and 1000 PFU)
Number of subjects: 36
Study 27521362 — intervention group
Group type: EXPERIMENTAL
Intervention: All seroconverters
Number of subjects: 36
Study 27522076 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) centered on parietal regions
Number of subjects: 0
Study 27522076 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of configural face differences
Number of subjects: 0
Study 27522076 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of featural face differences
Number of subjects: 0
Study 27522379 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening procedure (PEFR <80% of predicted and RHSQ >19.5 points)
Number of subjects: 169
Study 27522379 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-month health status in patients with undiagnosed COPD
Number of subjects: 169
Study 27522472 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated EHR extraction
Number of subjects: 150
Study 27522472 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicaid claims
Number of subjects: 150
Study 27524654 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenoprotein P (SeP) in overweight/obese individuals
Number of subjects: 63
Study 27524654 — intervention group
Group type: EXPERIMENTAL
Intervention: SEPP1 mRNA expression in subcutaneous adipose tissue
Number of subjects: 63
Study 27524739 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma leptin levels (quartiles)
Number of subjects: 1601
Study 27525031 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Atkins diet (20 to 40 g of carbohydrates daily)
Number of subjects: 17
Study 27525031 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Atkins diet
Number of subjects: 17
Study 27525046 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary treatment with extensively hydrolyzed casein formula containing Lactobacillus rhamnosus GG (group 2)
Number of subjects: 40
Study 27525046 — intervention group
Group type: EXPERIMENTAL
Intervention: Other formulas (group 3)
Number of subjects: 40
Study 27525046 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy controls (group 4)
Number of subjects: 40
Study 27525046 — intervention group
Group type: COMPARATOR
Intervention: Active IgE-mediated CMA (group 1)
Number of subjects: 40
Study 27525190 — intervention group
Group type: EXPERIMENTAL
Intervention: T3D-959 (1.0 mg/kg/day)
Number of subjects: 2
Study 27525190 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 2
Study 27525313 — intervention group
Group type: EXPERIMENTAL
Intervention: EPI-506
Number of subjects: 0
Study 27525313 — intervention group
Group type: EXPERIMENTAL
Intervention: galeterone
Number of subjects: 0
Study 27525313 — intervention group
Group type: COMPARATOR
Intervention: AR LBD-targeted therapies
Number of subjects: 0
Study 27525540 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide QW 2 mg
Number of subjects: 295
Study 27526051 — intervention group
Group type: EXPERIMENTAL
Intervention: Ab interno trabecular bypass surgery with Trabectome
Number of subjects: 19
Study 27526051 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical, laser, or surgical treatment
Number of subjects: 19
Study 27526051 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectome surgery with concomitant phacoemulsification
Number of subjects: 19
Study 27526051 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectome surgery without concomitant phacoemulsification
Number of subjects: 19
Study 27526059 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid-based formula for 12 weeks
Number of subjects: 30
Study 27526372 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac implantable electronic devices (CIED) implantation including 6 pacemakers (PM) and 6 cardiac resynchronization devices (CRT), 2 of which were defibrillators (CRT-D)
Number of subjects: 9
Study 27526372 — intervention group
Group type: EXPERIMENTAL
Intervention: CIED implantation
Number of subjects: 9
Study 27527001 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol
Number of subjects: 17
Study 27527001 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin
Number of subjects: 17
Study 27527001 — intervention group
Group type: EXPERIMENTAL
Intervention: SHBG
Number of subjects: 17
Study 27527001 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol and leptin ratio
Number of subjects: 17
Study 27527831 — intervention group
Group type: EXPERIMENTAL
Intervention: Helping Babies Breathe (HBB) training
Number of subjects: 70704
Study 27527831 — intervention group
Group type: COMPARATOR
Intervention: Control (pre-implementation period)
Number of subjects: 70704
Study 27528114 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment course for CRPC patients
Number of subjects: 0
Study 27528460 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol levels in PMD patients
Number of subjects: 0